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We report a case of treatment-related acute myeloid leukemia (t-AML) in a 16-year-
old male following treatment for osteosarcoma (OS). He had been treated with a 
protocol comprising neoadjuvant chemotherapy, definitive surgery with wide exci-
sion and adjuvant chemotherapy for OS. Four months after completion of the treat-
ment, a routine hemogram showed hyperleukocytosis with 90% blasts. Bone marrow 
aspirate and a chromosomal analysis disclosed acute myeloid leukemia (AML), M5b 
with 46, XY, t(11;19)(q23;p13.3). The t-AML was characterized by early develop-
ment (just 4 months after completion of chemotherapy for OS) and generalized 
leukemia cutis. The patient received an alkylating agent (ifosfamide) and DNA 
topoisomerase II-targeted drugs (etoposide and doxorubicin). In terms of latency, 
cytogenetics, and presentation, DNA topoisomerase II-targeted drug-related leuke-
mia seemed likely for this patient. Clinically, his leukemia cutis had developed 
during a nadir in white blood cell count after the first induction of chemotherapy 
for AML. The rapid progression and its refractoriness to chemotherapy were poor 
prognostic signs.
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1.  Introduction
Treatment-related malignancy is rare but has be-
come a growing concern over the past decades be-
cause of the improved survival of children with 
cancer. There is substantial information regarding 
treatment-related malignancies following Hodgkin 
disease and acute lymphoblastic leukemia because 
of the good cure rates for these, resulting in many 
long-term survivors. Franklin et al reported 705 
cases of secondary malignancies in 9312 Hodgkin 
disease patients with a follow-up of 5−27 years.1 
Hijiya et al reported treatment-related malignan-
cies in 1.2−3.3% of acute lymphoblastic leukemia 
patients with a follow-up of 10−15 years.2 In the 
last 30 years, the 5-year survival has increased from 
10% to 70% for primary osteosarcoma (OS).3 Because 
of the increased survival rate, there is increased con-
cern over treatment-related malignancy following 
OS. However, only a few papers discussed treatment-
related leukemia in OS. Bacci et al reported a rate 
of 2.16% (26/1205) for treatment-related malig-
nancy following OS in Italy between 1972 and 2001.4 
Ten of the cases were malignancies of hematopoietic 
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origin, and the interval between primary neoplasm 
and treatment-related malignancy ranged 1−17 
years (median 2.6 years). 
Here we describe a young adult with primary 
OS who developed treatment-related acute myeloid 
leukemia (t-AML) as early as 4 months after com-
pletion of chemotherapy (1.3 years after the diag-
nosis of OS). He developed generalized leukemia 
cutis, which was refractory to multi-agent chemo-
therapy. In this case study, we also review the 
types and prognosis of treatment-related leukemia 
in the literature, and analyze the results of another 
19 previously reported patients with leukemia fol-
lowing treatment of OS.
2.  Case Report
A 16-year-old male was diagnosed with high-grade 
OS, osteoblastic-type according to the pathological 
results of a tumor biopsy performed in December, 
2005. He initially presented with left knee pain, 
most often at night, for 2 months. Magnetic reso-
nance imaging revealed a large tumor in the meta-
diaphyseal region of the left femur (Figure 1). Tumor 
staging with computed tomography of the chest and 
a whole-body bone scan revealed no evidence of dis-
tant metastasis. The initial laboratory results showed 
elevated levels of alkaline phosphatase (406 U/L; 
reference range: 10−100 U/L) and lactate dehydro-
genase (544 U/L; reference range 95−213 U/L). 
Stage IIA OS (high grade, intracompartmental 
lesion, without metastasis) was diagnosed according 
to the Enneking staging system. The patient was 
treated using the modified TP-VGH OGS 001 proto-
col for non-metastatic extremity OS. He sequentially 
received induction chemotherapy, definitive limb-
salvage surgery with wide excision and a functional 
reconstruction with arthrodesis, and adjuvant che-
motherapy (Table 1). The pathology after limb-salvage 
surgery showed free of margin and 100% tumor necro-
sis rate, which indicated a good response to neo-
adjuvant chemotherapy. The treatment program 
was completed in December, 2006. The cumulative 
doses were etoposide 300 mg/m2, methotrexate 
108 g/m2, cisplatin 690 mg/m2, doxorubicin 420 mg/
m2, and ifosfamide 75 g/m2. Thereafter, the patient 
was followed up every 2 months at our pediatric 
clinic.
In April 2007, 4 months after the end of treat-
ment, a routine blood count revealed leukocytosis 
with 90% blasts, mild anemia and thrombocyto-
penia (leukocytes 202,600/μL, hemoglobin 10.3 g/
dL, platelets 54,000/μL). Physical examination re-
vealed marked gingival hypertrophy and gum bleed-
ing, with no hepatosplenomegaly. Acute leukemia 
was suspected and the patient was admitted for 
emergency leukapheresis. Bone marrow aspiration 
was done and a chromosomal analysis disclosed an 
abnormal clone with 46, XY, t(11;19)(q23;p13.3). 
The results for leukemia surface markers were 
HLA-DR: 99.8%; CD34: 1%; CD19: 0.9%; CD10: 0.2%; 
CD7: 0.1%; CD2: 5.0%; CD13: 98.2%; CD33: 99.8%; 
CD14: 89%, CD15: 74.2%; CD56: 88.3%. Cytochemical 
stain showed peroxidase: 96%; NES: 97%. Therefore, 
AML, M5b was diagnosed. 
Induction chemotherapy for AML with idarubicin 
(8 mg/m2 once daily intravenously for 3 consecutive 
days; total dose 24 mg/m2) and cytarabine (100 mg/
m2 once daily intravenously for 7 consecutive days; 
total dose 700 mg/m2) were administered. However, 
Figure 1 Magnetic resonance imaging of the left femur. 
A large tumor in the meta-diaphyseal region with sur-
rounding soft-tissue involvement and intact neurovascu-
lar bundles was found.
Table 1  Treatment protocol for this patient (modified from the TP-VGH-OGS 001 protocol for high-grade 
osteosarcoma)
 M I + V C + A M I C + A M OP M A* I M C* M A* I M C* M A* I M C*
Week 0 2 5 9 10 13 16 18 19 20 23 26 27 30 31 34 37 38 41 42 45 48 49
A = adriamycin (37.5 mg/m2/day IV drip for 24 hours ˜  2 days); A* = adriamycin (45 mg/m2/day IV drip for 24 hours ˜  2 days); C = cispla-
tin (60 mg/m2/day IV drip for 24 hours ˜  2 days); C* = cisplatin (75 mg/m2/day IV drip for 24 hours ˜  2 days); I = ifosfamide 2.4 g/m2/
day IV drip for 24 hours ˜  5 days on week 2, and 3.0 g/m2/day IV drip for 24 hours ˜  5 days on week 10, 23, 34, 45; M = methotrexate 
(12 gm/m2 IV drip for 4 hours ˜  1 day); OP = operation; V = VP − 16 (60 mg/m2/day IV drip for 1 hour ˜  5 days). 
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during the white blood cell nadir, leukemia cutis 
was noted with multiple violaceous papules and 
nodular skin lesions initially involving the trunk 
and which quickly disseminated to the entire body 
including the face, scalp, back and extremities 
(Figure 2). The second chemotherapy regimen was 
shifted to a FLAG regimen (fludarabine, cytarabine 
and granulocyte colony-stimulating factor).5 The 
patient’s skin lesions only partially and transiently 
responded to the regimen with a decrease in size 
1 week after the second course of chemotherapy. 
To control his refractory leukemia cutis, timed se-
quential chemotherapy with EMA-G regimens (etopo 
side, mitoxantrone, Ara-C and granulocyte colony-
stimulating factor) was applied.6 This was reported 
to be a safe and efficacious option for induction 
chemotherapy in advanced, high-risk AML patients. 
The generalized skin lesions subsided markedly in 
2 weeks with only some residual papules over the 
extremities. Unfortunately, during prolonged pan-
cytopenia, he became febrile and suffered from 
septic shock with multiple organ failure. The pa-
tient died on July 24, 2007, 3 months after the 
diagnosis of AML. 
3.  Discussion
The definition of secondary malignancy includes: 
(1) treatment-related malignancy secondary to 
chemotherapeutic treatment and/or radiation for 
a primary malignancy; and (2) non-therapy-induced 
secondary malignancy. Some gene carriers, includ-
ing individuals with inherited p53 mutation or 
Li-Fraumeni syndrome, are at risk of developing mul-
tiple synchronous or metachronous non-therapy-
induced secondary malignancy. Our patient had 
an unremarkable past medical and family history. 
His general appearance, growth and development 
were all within normal limits, and he was not con-
sidered to have a congenital or genetic disease at 
the time of diagnosis of OS. Although routine ge-
netic analysis is not performed at our institution, 
the development of leukemia in this case could 
only be presumed to be secondary to previous cy-
totoxic chemotherapy on a clinical basis.
There are two known types of treatment-related 
leukemia; the first type results from the use of an 
alkylating agent, and was first identified by Crosby 
et al in 1969. The second type, resulting from the 
use of DNA topoisomerase II-targeted drugs, was 
first identified in 1985.7 Many differences in features 
exist between the two types of chemotherapy-
related leukemia, as shown in Table 2.8−10 Alkylating 
agent-related leukemia is characterized by ante-
cedent myelodysplasia, a mean latency period of 3−7 
years and a complete or partial deletion of chro-
mosome 5 or 7. DNA topoisomerase II-targeted drug-
related leukemia is characterized by translocations 
of the MLL gene at chromosome band 11q23 or other 
less common chromosome translocations, and a 
mean latency period of 2 years, shorter than the 
former type. Our patient received both an alkylating 
agent (ifosfamide) and DNA topoisomerase II-targeted 
drugs (etoposide, doxorubicin). He developed AML, 
M5b, t(11;19)(q23;p13.3), 1.3 years after the diag-
nosis of OS and 4 months after completion of treat-
ment. In the context of a short latency, the t(11q23) 
cytogenetics (a common chromosomal abnormality 
in secondary acute leukemia and myelodysplastic 
syndrome) and the M5 presentation, the DNA topoi-
somerase II-targeted drugs were the most likely 
cause for the development of leukemia.11 Further-
more, both etoposide and doxorubicin have been 
reported to be possible causative agents in treat-
ment-related leukemia.12,13 
We have summarized the karyotype analysis of 
the 19 previously reported patients and our patient 
in Table 3.13−27 We found that the majority of leuke-
mias that occur after treatment of OS were associ-
ated with the use of topoisomerase II-targeted drugs, 
particularly doxorubicin (19 out of 20 patients). It 
has been reported that the risk of t-AML increases 
when the total dose of etoposide exceeds 2.0 g/m2.12 
However, some authors have suggested that there is 
no safe dose for etoposide.28 Accordingly, although 
the cumulative dosage of etoposide our patient re-
ceived was only 300 mg/m2 (60 mg/m2 daily intra-
venously for 5 days; cumulative dose, 300 mg/m2 ), 
the causal relationship of etoposide and the t-AML 
could not be ruled out definitively.
Compared with de novo AML, the incidence of 
clonal chromosome abnormality is higher and the 
prognosis is much poorer in t-AML.10 An aberrant 
karyotype was detected in 86% of t-AML and in 
Figure 2 Image of the patient showing leukemia cutis, 
which initially developed during a white cell nadir after 
the first induction chemotherapy. 
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Table 3  Characteristics of the 20 treatment-related leukemia patients (including the present case) following 
treatment of osteosarcoma. The cumulative doses of chemotherapy and outcomes are shown 
Patient Age*/ IFO DOX Etoposide Radiation Interval† to FAB 
Chromosome Outcome‡ Reference
 
No. gender (g/m2) (mg/m2) (mg/m2) (Gy) leukemia
1 28/F − 420 − 35 24 ? Normal D (8) 14
2 20/M −  +  − − ? M2 t(8q;21q) A (3) 15
3 17/F −  +  − − 11 M4 t(9p;11q) A 15
4 24/F − 540 − 70 98 M2 t(8q;21q) D (16) 16
5 22/F ? ? − − 80 ?  + 7, −10, −20, −21 ? 17
6 17/M −  +  − − ? M5 Dup(1q), + 3, + 9 A (24)  18
7 14/M 36 300 − −  9 L1 t(4q;11q) D (4) 19
8 12/F −  +  − −  1 RAEB −5, −7 A (11) 20
9 15/M −  +  − ? 38 ? ? A (80) 21
10 11/F − 390 − − 16 M4 Normal D (1 /30) 22
11 16/M − 465 − − 28 M2 t(8q;21q) D (24) 22
12 11/F − 480 − − 12 L1 Normal A (60) 23
13 22/F −  +   +  53 32 M2 t(8q;21q) A (3) 24
14 15/F 4.5 570 4000 66 14 ANLL − 5, −7, −17 D 25
15 13/F − 405 − − 26 M4 Normal A (17) 13
16 21/M 108 280 − − 21 M2 t(8q;21q) D (10) 13
17 14/M 4.5 620 − −  9 M0 −7(7q31) A (29) 26
18 8/M 54 450 − −  5 M5 t(9;11)(p21;q23) D (7) 26
19 14/M −  +  − −  8 CMML t(9;11)(p22;q23) D (1/30) 27
Our case 16/M 75 420 300 −  4 M5 t(11,19)(q23;p13) D (4)
*Age in years; †duration (months) between complete treatment of osteosarcoma to development of leukemia; ‡Duration (months) 
between the onset of treatment-related leukemia to the patient’s death or time of last follow-up; +  = received; − = not received; 
? = no information; A = alive; ANLL = acute nonlymphocytic leukemia; CMML = chronic myelomonocytic leukemia; D = died; DOX = doxo-
rubicin; F = female; FAB = French-American-British classification; L1 = acute lymphoblastic leukemia; M = male; IFO = ifosfamide; 
M0 = acute myeloid leukemia with minimal differentiation; M2 = acute myeloblastic leukemia with differentiation; M4 = acute 
myelomonocytic leukemia; M5 = acute monocytic leukemia; RAEB = refractory anemia with excess blasts; VP − 16 = etoposide.
Table 2  Clinical characteristics of alkylating agent-related and DNA topoisomerase II-targeted drug-related 
leukemia
 Alkylating agent-related DNA topoisomerase II-targeted drug-related
Presentation Myelodysplasia FAB M4/M5 AML, other AML,
  Myelodysplasia, ALL, CML
Latency* 36−84 months 6−36 months
Incidence 1 to > 20% 2−12%
Risk factor Alkylating agent dose, Intermittent schedule†, 
 radiation, splenectomy, age  L-asparaginase, primary ALL
Predisposition Germline p53 mutation,  Unknown
 germline NF-1 mutation, 
 GSTT1 null genotype(?)
Cytogenetics −5, −7, del(5q), del(7q) t(11q23), t(21q22), t(8;21), t(3;21), 
  inv(16), t(8;16), t(15;17), t(9;22), 
  t(11;11)(p13∼p15;q23)
Molecular Tumor suppressor gene(s),  Translocations 
 RAS mutation 
*Interval from drug exposure to onset of leukemia; †weekly or twice weekly; AL = acute lymphocytic leukemia; AML = acute 
myeloid leukemia; CML = chronic myelogenous leukemia; FAB = French-American-British classification; M4 = acute myelomonocytic 
leukemia; M5 = acute monocytic leukemia.
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57.6% of de novo AML (p < 0.00001).10 The median 
overall survival of 1091 cases with de novo AML was 
15 months, compared with only 10 months in t-AML 
(p = 0.0007).10 When patients were grouped 
according to cytogenetics into three categories 
(favorable, intermediate or unfavorable), the data 
analyses revealed that cytogenetics are an impor-
tant prognostic parameter for t-AML. The cytoge-
netic profile of our patient was categorized into 
the unfavorable group according to previous re-
ports. The median overall survival for patients 
with t-AML and an unfavorable cytogenetic profile 
was only 6 months.10
In our patient, leukemia cutis was diagnosed 
clinically by typical skin features (multiple viola-
ceous papules and nodules disseminated over the 
trunk, extremities and face) and a typical response 
to treatment (disappearance of the skin lesions 
after chemotherapy).29,30 A skin biopsy could not 
be attained because of failure to obtain the family’s 
consent. Leukemia cutis is a rare but well-known 
extramedullary manifestation of AML.30,31 However, 
there is limited information about the association 
between leukemia cutis and treatment-related 
leukemia. The majority of patients with leukemia 
cutis had the AML FAB-M4 or M5 subtype, inv(16), 
t(9;11), t(8;21) and numerous aberrations in chro-
mosome 8.30,31 In a well-characterized cohort of pa-
tients with de novo AML, there was no statistical 
significance with regard to treatment outcome of AML 
with or without leukemia cutis.30 However, based 
on the experience of this case study, the general-
ized leukemia cutis developed during a white blood 
cell nadir, was potentially refractory to conventional 
chemotherapy or second-line chemotherapy, and 
carried a dismal prognosis.
4.  Conclusions
In conclusion, this patient developed t-AML with 
aggressive leukemia cutis shortly after treatment 
for OS. The patient did not reach complete remission 
despite the application of three different chemo-
therapeutic regimens. His t-AML was considered to 
be associated with previously used topoisomerase 
II-targeted drugs, and was refractory to multi-
agent chemotherapy. The prognosis for OS patients 
with chemotherapy-induced t-AML is poor, particu-
larly when leukemia cutis develops concomitantly.
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